• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CEO and President Elsesser Adam exercised 27,976 shares at a strike of $30.00 and sold $4,818,006 worth of shares (16,650 units at $289.37), increasing direct ownership by 18% to 75,237 units (SEC Form 4)

    5/9/25 7:35:53 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care
    Get the next $PEN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Elsesser Adam

    (Last) (First) (Middle)
    ONE PENUMBRA PLACE

    (Street)
    ALAMEDA CA 94502

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Penumbra Inc [ PEN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO and President
    3. Date of Earliest Transaction (Month/Day/Year)
    05/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/07/2025 M 27,976 A $30 91,887 D
    Common Stock 05/07/2025 S(1) 3,350 D $287.26(2) 88,537 D
    Common Stock 05/07/2025 S(1) 4,500 D $288.25(3) 84,037 D
    Common Stock 05/07/2025 S(1) 2,924 D $289.45(4) 81,113 D
    Common Stock 05/07/2025 S(1) 3,205 D $290.31(5) 77,908 D
    Common Stock 05/07/2025 S(1) 956 D $291.62(6) 76,952 D
    Common Stock 05/07/2025 S(1) 50 D $292.41 76,902 D
    Common Stock 05/07/2025 S(1) 1,575 D $293.21(7) 75,327 D
    Common Stock 05/07/2025 S(1) 90 D $295 75,237 D
    Common Stock 837,582 I By Trust(8)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $30 05/07/2025 M 27,976 (9) 09/16/2025 Common Stock 27,976 $0 251,788 D
    Explanation of Responses:
    1. The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. The Reporting Person entered into the Rule 10b5-1 trading plan in connection with the expiration of certain stock options held by the Reporting Person and related sales of shares to satisfy the exercise price and tax withholding obligations upon the exercise of such stock options.
    2. This transaction was executed in multiple trades at prices ranging from $286.87 to $287.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
    3. This transaction was executed in multiple trades at prices ranging from $287.87 to $288.65. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
    4. This transaction was executed in multiple trades at prices ranging from $288.96 to $289.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
    5. This transaction was executed in multiple trades at prices ranging from $289.91 to $290.85. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
    6. This transaction was executed in multiple trades at prices ranging from $291.08 to $291.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
    7. This transaction was executed in multiple trades at prices ranging from $293.00 to $293.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
    8. Shares are held by the Siegel/Elsesser Revocable Trust.
    9. All shares are vested and exercisable.
    Remarks:
    /s/ Johanna Roberts, as attorney-in-fact for Adam Elsesser 05/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PEN

    DatePrice TargetRatingAnalyst
    3/14/2025$320.00Buy
    BofA Securities
    1/21/2025$305.00Buy
    UBS
    12/17/2024$275.00Outperform
    Oppenheimer
    12/11/2024$190.00 → $275.00Equal Weight → Overweight
    Wells Fargo
    9/18/2024$238.00Buy
    Stifel
    9/3/2024$263.00Outperform
    Leerink Partners
    7/31/2024$289.00 → $150.00Overweight → Equal Weight
    Wells Fargo
    7/31/2024$165.00 → $178.00Buy → Neutral
    Citigroup
    More analyst ratings

    $PEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

      ALAMEDA, Calif., April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Event:     BofA Securities 2025 Health Care ConferenceDate:       Tuesday, May 13, 2025Time:      6:00pm ET/3:00pm PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com.  The webcast will be available on the company's website for at least two weeks followi

      4/29/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Reports First Quarter 2025 Financial Results

      ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income

      4/23/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

      ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the

      4/3/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Penumbra with a new price target

      BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00

      3/14/25 7:46:38 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on Penumbra with a new price target

      UBS initiated coverage of Penumbra with a rating of Buy and set a new price target of $305.00

      1/21/25 8:26:37 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Oppenheimer initiated coverage on Penumbra with a new price target

      Oppenheimer initiated coverage of Penumbra with a rating of Outperform and set a new price target of $275.00

      12/17/24 7:54:12 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Financials

    Live finance-specific insights

    See more
    • Penumbra, Inc. Reports First Quarter 2025 Financial Results

      ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income

      4/23/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

      ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the

      4/3/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023.Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian governme

      2/18/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/14/24 1:22:36 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/12/24 12:53:28 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Penumbra Inc.

      SC 13G - Penumbra Inc (0001321732) (Subject)

      2/14/24 10:03:02 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Penumbra Inc.

      10-Q - Penumbra Inc (0001321732) (Filer)

      4/23/25 4:44:54 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Penumbra Inc (0001321732) (Filer)

      4/23/25 4:14:52 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Penumbra Inc.

      DEFA14A - Penumbra Inc (0001321732) (Filer)

      4/16/25 4:29:05 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

      Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i

      10/10/24 9:00:00 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors

      SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma

      10/24/22 8:30:00 AM ET
      $BLZE
      $GSIT
      $PEN
      Computer Software: Prepackaged Software
      Technology
      Semiconductors
      Medical/Dental Instruments

    $PEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Elsesser Adam exercised 27,976 shares at a strike of $30.00 and sold $4,818,006 worth of shares (16,650 units at $289.37), increasing direct ownership by 18% to 75,237 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      5/9/25 7:35:53 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Yuen Maggie exercised 900 shares at a strike of $158.30 and sold $598,020 worth of shares (2,000 units at $299.01), decreasing direct ownership by 7% to 14,857 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      5/6/25 7:30:45 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Director Bose Arani sold $3,584,775 worth of shares (12,000 units at $298.73), decreasing direct ownership by 4% to 302,819 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      4/29/25 7:34:22 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care